Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission - StockTitan
XSPRAY Stock | SEK 29.25 5.30 15.34% |
About 62% of XSpray Pharma's investor base is looking to short. The analysis of current outlook of investing in XSpray Pharma AB suggests that many traders are alarmed regarding XSpray Pharma's prospects. The current market sentiment, together with XSpray Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use XSpray Pharma AB stock news signals to limit their universe of possible portfolio assets.
XSpray |
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission StockTitan
Read at news.google.com
XSpray Pharma Fundamental Analysis
We analyze XSpray Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XSpray Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XSpray Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
XSpray Pharma is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
XSpray Pharma AB Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with XSpray Pharma stock to make a market-neutral strategy. Peer analysis of XSpray Pharma could also be used in its relative valuation, which is a method of valuing XSpray Pharma by comparing valuation metrics with similar companies.
Peers
XSpray Pharma Related Equities
CANTA | Cantargia | 1.19 | ||||
BIOA-B | BioArctic | 1.08 | ||||
HNSA | Hansa Biopharma | 0.69 | ||||
VICO | Vicore Pharma | 4.70 | ||||
XBRANE | Xbrane Biopharma | 5.88 |
Complementary Tools for XSpray Stock analysis
When running XSpray Pharma's price analysis, check to measure XSpray Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XSpray Pharma is operating at the current time. Most of XSpray Pharma's value examination focuses on studying past and present price action to predict the probability of XSpray Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XSpray Pharma's price. Additionally, you may evaluate how the addition of XSpray Pharma to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Stocks Directory Find actively traded stocks across global markets |